DeepUll, a Barcelona, Spain-based medical diagnostics company, announced that it raised €13 million in a Series B round of funding.
The round was led by new investors Innvierte, part of the Spanish Ministry of Science and Innovation (CDTI), and an undisclosed strategic investor, as well as participation from existing investors Kurma Partners, Alta Life Sciences, UI Investissement (advised by Mérieux Equity Partners) and Axis Participaciones Empresariales.
The funds will be used to progress the development of DeepUll’s first-in-class sepsis recognition platform in the market.
Jordi Carrera, Chief Executive Officer and co-founder of DeepUll, says, “Early identification of sepsis is absolutely crucial to a patient’s prognosis, but the tools caregivers have available today are woefully inadequate. Our mission is to change this, and this financing will allow us to ramp up our efforts to bring our first-in-class sepsis recognition platform to market. We are grateful to our existing investors and excited to welcome our new investors, which will strengthen our investor base.”
DeepUll’s technology aims to not only rapidly identify the causative infective agent(s) within a few hours but will also provide phenotypic antimicrobial susceptibility results, reducing the unnecessary use of antimicrobials.
Company: Deepull Diagnostics SL
Round: Series B
Funding Month: October 2022
Lead Investors: Innvierte
Additional Investors: Kurma Partners, Alta Life Sciences, UI Investissement (advised by Mérieux Equity Partners), and Axis Participaciones Empresariales
Software Category: Medical Diagnostics Solutions for Sepsis and Acute Infections
About the Company: Founded in 2020 by Jordi Carrera and Rafel Bru, DeepUll develops culture-free diagnostic solutions for sepsis and acute infections. The company’s product can detect more than 250 pathogens and about 15 resistance genes in one hour, with only 10mL of whole blood. Additionally, it provides phenotypic antimicrobial susceptibility results, reducing the unnecessary use of antimicrobials. DeepUll’s product is powered by Artificial Intelligence (AI) and offers medical decision support across all phases of patient management, from early disease recognition to precise diagnostics, up to therapy guidance. The product will generate phenotypic antimicrobial susceptibility results in about eight hours without requiring a positive blood culture. The product will be a desktop system with end-to-end automation to be placed in any clinical setting (laboratory, ER, ICU).